TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30218286
Drug: Probiotic honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic honey (25 g/day containing Bacillus coagulans T11, 108 CFU/g)
Study: 30218286
Drug: Control honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control honey (25 g/day)
Study: 28515164
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (FeFol) tablets
Study: 28515164
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) tablets
Study: 28515164
Drug: Protein energy
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein energy (PE) as a lipid‐based nutrient supplement (LNS)
Study: 23748441
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of netupitant and palonosetron (NEPA)
Study: 11501851
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS fentanyl) starting at 25 microg/hour, titrated to a mean of 87.4 microg/hour by day 56.
Study: 11501851
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS fentanyl) with incremental steps of 25 microg/hour.
Study: 11501851
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS fentanyl) with immediate release oral morphine (5 mg) every 4-6 hours for the first 12 hours.
Study: 11501851
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS fentanyl) with follow-up assessments by palliative care team.
Study: 11501851
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS fentanyl) with Karnofsky scale measurements.
Study: 3144542
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G 2.4 million units intramuscular plus 1.0 g probenecid orally
Study: 3144542
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Fleroxacin and Penicillin G with Probenecid)
Study: 23477421
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10^7 piece/mL bone marrow mononuclear cell transplant
Study: 16480406
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Study: 16480406
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Study: 12831624
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 1-2 mg/kg
Study: 12831624
Drug: Intravenous procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procaine anesthesia (IPA)
Study: 8756933
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion (0.3 U/min)
Study: 1359322
Drug: Pentamidine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine 4 mg/kg intramuscular injections on alternate days (20 doses)
Study: 1359322
Drug: Amphotericin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphotericin 0.5 mg/kg infused in 5% dextrose on alternate days (14 doses)
Study: 21293163
Drug: Reduced-fluence verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reduced-fluence verteporfin photodynamic therapy (PDT) with 25 mJ/cm², intravitreal ranibizumab 0.3 mg/0.05 ml, intravitreal dexamethasone 200 μg, and oral minocycline 100 mg daily for 3 months
Study: 15523353
Drug: 0.5 minimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 minimal phototoxic dose (MPD) 4 times/wk
Study: 15523353
Drug: 1 MPD
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 MPD twice/wk
Study: 15523353
Drug: 0.5 MPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 MPD twice/wk
Study: 15523353
Drug: 0.75 MPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 MPD twice/wk
Study: 11397860
Drug: KTCZ (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTCZ (400 mg orally 4 times daily)
Study: 11397860
Drug: KTCZ +
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTCZ + transdermal testosterone (7.5 mg daily)
Study: 11397860
Drug: KTCZ +
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTCZ + transdermal estradiol (0.05 mg daily)
Study: 11397860
Drug: KTCZ +
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTCZ + testosterone + anastrazole (5 mg orally twice daily)
Study: 935298
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment (including placebo)
Study: 21320256
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for mania and maintenance studies
Study: 21320256
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for depression studies
Study: 21320256
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment in maintenance studies
Study: 11561075
Drug: Nizatidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (600 mg)
Study: 11561075
Drug: Famotidine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (80 mg)
Study: 3315285
Drug: L-leucine (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-leucine (2-g oral dose)
Study: 3315285
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without L-leucine)
Study: 29352828
Drug: Zn-fortified filtered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn-fortified filtered water (2.8 mg Zn/d)
Study: 26786000
Drug: G‐hesperidin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐hesperidin with 50 mg caffeine
Study: 26786000
Drug: G‐hesperidin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐hesperidin with 75 mg caffeine
Study: 26786000
Drug: G‐hesperidin with/without
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐hesperidin with/without caffeine
Study: 21042200
Drug: Bupivacaine sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine sciatic block with intramuscular buprenorphine (0.3 mg)
Study: 18186954
Drug: Topical ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketamine (0.4 mL, 20 mg) in 10 mL artificial saliva
Study: 18186954
Drug: Topical ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketamine (0.4 mL, 20 mg) + morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Study: 18186954
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Study: 18186954
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mL artificial saliva)
Study: 16444450
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d pravastatin
Study: 15566456
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion of 5000 U, starting 3 h before the administration of anti-neoplastic agents and continuing for 12 h
Study: 15566456
Drug: Anti-neoplastic agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-neoplastic agents alone (Control)
Study: 11774859
Drug: Benidipine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (once daily, 4 mg/d, in the morning)
Study: 11774859
Drug: Nifedipine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (twice daily, 20 mg/d)
Study: 8344693
Drug: mAb IOT4A
Normalized name: Carrageenan-iota
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb IOT4A (0.6 mg, 1.2 mg, 2.4 mg)
Study: 31701153
Drug: Gradual nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual nicotine reduction (15.5, 11.7, 5.2, 2.4, and 0.4 mg/g)
Study: 31701153
Drug: Immediate nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate nicotine reduction (0.4 mg/g)
Study: 31701153
Drug: Standard nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nicotine content cigarettes (15.5 mg/g; control)
Study: 29752304
Drug: Eteplirsen 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eteplirsen 30 or 50 mg/kg IV once weekly
Study: 18284400
Drug: Tacrolimus gel
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus gel 0.3%
Study: 18284400
Drug: Tacrolimus cream
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus cream 0.5%
Study: 18284400
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment 0.005%
Study: 16368287
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T 0.01 to 0.10 ng/mL
Study: 16368287
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T > 0.10 ng/mL
Study: 12502990
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene infusion of 2 mg/ml ropivacaine at 6 or 9 ml/h for 48 hours
Study: 12502990
Drug: Initial interscalene
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial interscalene block with 30 ml ropivacaine, 7.5 mg/ml (225 mg)
Study: 8885726
Drug: Inpatient management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient management with bed rest, weekly corticosteroids until 32 weeks, and ultrasonographic examination at 2-week intervals.
Study: 8885726
Drug: Outpatient management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient management with discharge after >72 hours of hospitalization, weekly corticosteroids until 32 weeks, and ultrasonographic evaluations.
Study: 1550636
Drug: Spontaneous labor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spontaneous labor with oxytocin augmentation
Study: 6094450
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefotaxime
Study: 29055489
Drug: NICE guidance
Normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NICE guidance on tumor necrosis factor inhibitor (TNFi) therapies
Study: 27181456
Drug: Early strategy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early strategy of renal-replacement therapy (initiated immediately after randomization)
Study: 27181456
Drug: Delayed strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed strategy of renal-replacement therapy (initiated based on specific criteria)
Study: 27181456
Drug: Early strategy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early strategy of renal-replacement therapy
Study: 27181456
Drug: Delayed strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed strategy of renal-replacement therapy
Study: 25528663
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) dalteparin
Study: 22851600
Drug: Continuing Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuing Liraglutide 1.2 mg/day
Study: 22851600
Drug: Continuing Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuing Liraglutide 1.8 mg/day
Study: 17575559
Drug: Intravenous sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sitagliptin doses (25, 50, 100 mg)
Study: 17575559
Drug: Oral sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sitagliptin 100 mg after high fat meal
Study: 17575559
Drug: Oral sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sitagliptin 100 mg fasted
Study: 16354317
Drug: Gemcitabine followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine followed by docetaxel (1,000 mg/m2 for gemcitabine and 35 mg/m2 for docetaxel, given on days 1, 8, and 15 every 4 weeks)
Study: 16354317
Drug: Docetaxel followed
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel followed by gemcitabine (35 mg/m2 for docetaxel and 1,000 mg/m2 for gemcitabine, given on days 1, 8, and 15 every 4 weeks)
Study: 7852533
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) substitution therapy (0.05 U/kg.day for 1 year; 0.03 U/kg.day during the first month)
Study: 7191651
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of diazepam and 20 to 200 mg of methohexital intravenously
Study: 7191651
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of diazepam, 20 to 200 mg of methohexital, and 0.1 mg of fentanyl intravenously
Study: 22989372
Drug: Repeated high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated high‐dose bronchial allergen challenges with household dust mites for four consecutive days
Study: 22989372
Drug: Repeated high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated high‐dose bronchial allergen challenges
Study: 11943949
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/day, orally, 5 days/week)
Study: 9813932
Drug: standard 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard 750 ml volumatic spacer
Study: 8137628
Drug: 200mg RU
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg RU 486 followed by 5mg 9-methylene-PGE2 gel
Study: 8137628
Drug: 600mg RU
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg RU 486 with 3mg or 5mg 9-methylene-PGE2 gel
Study: 8137628
Drug: 200mg RU
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg RU 486 followed by 3mg 9-methylene-PGE2 gel
Study: 2573300
Drug: Terfenadine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (all doses)
Study: 2573300
Drug: Terfenadine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (active drug)
Study: 26507526
Drug: Combined IV
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IV and topical TXA
Study: 23340559
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplementation (twice daily)
Study: 18505181
Drug: APL 600
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 600 mg twice daily
Study: 18505181
Drug: APL 800
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 800 mg twice daily
Study: 11199313
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (1.8 m2, 220 ml)
Study: 11199313
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (2.5 m2, 270 ml)
Study: 11199313
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (2.2 m2, 290 ml)
Study: 9700445
Drug: One of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of six different therapies
Study: 7871449
Drug: Ceftriaxone, ampicillin/probenecid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, ampicillin/probenecid, amoxicillin/probenecid, spectinomycin
Study: 29129443
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (15 mg/kg intravenously every 21 days for 1 year)
Study: 26852501
Drug: Resonance-microwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonance-microwave therapy with the Akvaton-02 apparatus
Study: 26852501
Drug: Resonance-microwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonance-microwave therapy
Study: 21483892
Drug: Bio‐Oss Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Oss Collagen augmentation
Study: 18328638
Drug: Drug Counseling-as-usual
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Counseling-as-usual
Study: 16907900
Drug: Capsaicin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.5 mg, t.d.s for 7 days)
Study: 10669281
Drug: Ephedrine 0.5
Normalized name: Ephedrine 0.5% Nasal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.5 mg/kg i.m.
Study: 26970957
Drug: Resistance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance and Endurance exercise After ChemoTherapy (REACT)
Study: 16785738
Drug: Prednisolone alone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone alone (1 mg/kg BW/day)
Study: 16785738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisolone (0.5 mg/kg BW/day) with azathioprine (2 mg/kg BW/day) or cyclosporine (3 mg/kg BW/day)
Study: 16785738
Drug: No immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunosuppressive drugs (Control group)
Study: 16785738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lower prednisolone dose with azathioprine and cyclosporin
Study: 14718058
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching gel for 8 hours per day for 1 week (Group 2)
Study: 14718058
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium ascorbate treatment (Group 3)
Study: 11723415
Drug: Medroxyprogesterone‐acetate (MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone‐acetate (MPA) (10 mg/day) with continuous transdermal estradiol (TE) (50 microg/day)
Study: 11723415
Drug: Vaginal danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal danazol (200 mg/day) with continuous TE
Study: 9469532
Drug: Intranasal inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal inflammation induced by cold air (145 ml/s) with varying humidity and temperature
Study: 3540139
Drug: B subunit‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit‐killed whole cell (BS‐WC) cholera vaccine
Study: 3540139
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell‐only (WC) cholera vaccine
Study: 3540139
Drug: Control agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control agent
Study: 27939054
Drug: DTaP-IPV-HB-PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP-T vaccine co-administered with MenC vaccine (Group 1; n=175)
Study: 27939054
Drug: DTaP-IPV-HB-PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP-T vaccine without MenC vaccine (Group 2; n=175)
Study: 25677790
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: Conventional 120-kVp protocol with standard CM dose (280 mg iodine/kg body weight)
Study: 25677790
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: 80-kVp with 25% CM dose reduction (210 mg iodine/kg body weight)
Study: 25677790
Drug: Protocol C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C: 80-kVp with 50% CM dose reduction (140 mg iodine/kg body weight)
Study: 21440942
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 4 mg intravitreal triamcinolone
Study: 19004201
Drug: Yiweikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiweikang Capsule
Study: 19004201
Drug: Wenweishu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenweishu Capsule
Study: 9291901
Drug: Constant-rate infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-rate infusion
Study: 3525369
Drug: Sclerotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy plus oral propranolol (dose sufficient to reduce resting pulse rate by 25%)
Study: 31294749
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg/kg every 3 weeks) after 3 doses of 8 Gy stereotactic body radiotherapy
Study: 31294749
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg/kg every 3 weeks) alone (control arm)
Study: 23434449
Drug: Penehyclidine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine hydrochloride (0.05 mg/kg IV 10 minutes before cardiopulmonary bypass)
Study: 19876674
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) with varied administration of exposure
Study: 9207282
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg, 3 mL intramuscular injection)